$PD-L1 Expression on Circulating Tumour Cells May Be Predictive of Response to Regorafenib in Patients Diagnosed with Chemorefractory Metastatic Colorectal Cancer$

PD-L1 Expression on Circulating Tumour Cells May Be Predictive of Response to Regorafenib in Patients Diagnosed with Chemorefractory Metastatic Colorectal Cancer

<b>Keywords: </b>chemorefractory metastatic colorectal cancer; regorafenib; circulating tumour cells; PD-L1; PLR; liquid biopsy; acquired resistance; targeted therapy

Bibliographic Details
Main Authors:	Lucrezia Raimondi, Filippo Maria Raimondi, Laura Di Benedetto, Giuseppe Cimino, Gian Paolo Spinelli
Format:	Article
Language:	English
Published:	MDPI AG 2020-09-01
Series:	International Journal of Molecular Sciences
Subjects:	n/a
Online Access:	https://www.mdpi.com/1422-0067/21/18/6907

Similar Items

Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study
by: Keigo Chida, et al.
Published: (2021-04-01)

The role of FOLFOXIRI in chemorefractory metastatic colorectal cancer patients
by: Ibrahim Yildiz, et al.
Published: (2018-04-01)

Readministration of Cancer Drugs in a Patient with Chemorefractory Metastatic Colorectal Cancer
by: Tetsuro Kawagoe, et al.
Published: (2020-01-01)

Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer
by: Geva R, et al.
Published: (2013-01-01)

Practical considerations in the use of regorafenib in metastatic colorectal cancer
by: Fotios Loupakis, et al.
Published: (2020-10-01)

The role of regorafenib in the treatment of metastatic colorectal cancer
by: A A Tryakin
Published: (2016-06-01)

Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib
by: Barbara Melosky
Published: (2016-01-01)

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
by: Kawakami K, et al.
Published: (2019-10-01)

Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study
by: Anant Ramaswamy, et al.
Published: (2019-01-01)

Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer
by: Toshiki Masuishi, et al.
Published: (2019-11-01)

Assessment of Resistance Mechanisms and Clinical Implications in Patients with KRAS Mutated-Metastatic Breast Cancer and Resistance to CDK4/6 Inhibitors
by: Lucrezia Raimondi, et al.
Published: (2021-04-01)

Using of multi-kinase inhibitor regorafenib for metastatic colorectal cancer
by: O I Kit, et al.
Published: (2017-06-01)

Regorafenib application in patients with metastatic colorectal cancer in actual clinical practice
by: M I Sekacheva, et al.
Published: (2016-09-01)

Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer.
by: Yoojoo Lim, et al.
Published: (2015-01-01)

The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice
by: Yoon SE, et al.
Published: (2018-12-01)

Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer
by: Liying Sun, et al.
Published: (2021-10-01)

High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib
by: Alessio Amatu, et al.
Published: (2019-07-01)

Long-Lasting Tumor Response in Patients with Panitumumab Monotherapy for Chemorefractory Metastatic Colorectal Carcinoma – A Report of Two Cases
by: G. Ramadori, et al.
Published: (2010-05-01)

Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice
by: Margherita Nannini, et al.
Published: (2017-12-01)

Modern perspectives in sequential therapy for metastatic colorectal cancer with reference to the use of regorafenib
by: M. I. Sekacheva, et al.
Published: (2020-11-01)

Efficacy of Regorafenib in Metastatic Colorectal Cancer: A Multi-institutional Retrospective Study
by: Ali Aljubran, et al.
Published: (2019-01-01)

Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management
by: Khan G, et al.
Published: (2014-03-01)

Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report
by: Kenji Yoshino, et al.
Published: (2017-08-01)

The use of regorafenib in colorectal cancer
by: Marina I Sekacheva, et al.
Published: (2019-06-01)

The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study
by: Jisheng Li, et al.
Published: (2020-11-01)

Monitoring levels of circulating cell‐free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment
by: Brice Pastor, et al.
Published: (2021-09-01)

Сonfirmatory study of the efficacy and tolerability of trifluridine/tipiracil (TAS-102) therapy in the Russian population with chemorefractory metastatic colorectal cancer
by: M. Yu. Fedyanin, et al.
Published: (2020-12-01)

Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy
by: Florian Huemer, et al.
Published: (2020-09-01)

Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice
by: Fabien Calcagno, et al.
Published: (2016-07-01)

Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice
by: Fabien Calcagno, et al.
Published: (2016-01-01)

Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients
by: Novakova-Jiresova A, et al.
Published: (2020-07-01)

Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report
by: Tang R, et al.
Published: (2015-11-01)

Combination chemotherapy with Regorafenib in metastatic colorectal cancer treatment: A single center, retrospective study.
by: Chun-Yu Lin, et al.
Published: (2018-01-01)

Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting
by: Cheng-Jen Ma, et al.
Published: (2019-03-01)

A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer.
by: Yuji Miyamoto, et al.
Published: (2020-01-01)

Stunning Response with Low-Dose Enzalutamide after Abiraterone Acetate Failure in a Patient Diagnosed with Metastatic Castration-Resistant Prostate Cancer: A Case Report
by: Luigi Rossi, et al.
Published: (2021-03-01)

Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan
by: Kun-Huei Yeh, et al.
Published: (2021-11-01)

Correction: Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case
by: Matteo Fassan, et al.
Published: (2019-04-01)

Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
by: Dennis Doleschel, et al.
Published: (2021-09-01)

Treatment Outcomes of Metastatic Colorectal Cancer Patients Treated with Regorafenib as Third-Line Setting-A Multicenter Study
by: Süleyman Şahin, et al.
Published: (2019-03-01)